Armata Pharmaceuticals, Inc. (ARMP) financial statements (2020 and earlier)

Company profile

Business Address 4503 GLENCOE AVENUE
MARINA DEL REY, CA 90292
State of Incorp. WA
Fiscal Year End December 31
SIC 2836 - Biological Products, Except Diagnostic Substances (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments985697
Cash and cash equivalents985697
Receivables   000
Disposal group, including discontinued operation1     
Other undisclosed current assets100110
Total current assets:10856107
Noncurrent Assets
Property, plant and equipment311111
Intangible assets, net (including goodwill)1435102020
Goodwill3   88
Intangible assets, net (excluding goodwill)1035101212
Restricted cash and investments1     
Other noncurrent assets0     
Other undisclosed noncurrent assets200000
Total noncurrent assets:1936122122
TOTAL ASSETS:291211183129
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:132211
Accounts payable 11   
Employee-related liabilities 11100
Interest and dividends payable 000  
Other undisclosed accounts payable and accrued liabilities100111
Debt   1  
Deferred compensation liability2     
Due to related parties    0 
Business combination, contingent consideration, liability1     
Deferred revenue and credits  00
Other liabilities   0  
Other undisclosed current liabilities1  110
Total current liabilities:532422
Noncurrent Liabilities
Liabilities, other than long-term debt111533
Deferred tax liabilities, net11233
Business combination, contingent consideration, liability1     
Derivative instruments and hedges, liabilities 002  
Other undisclosed noncurrent liabilities5   118
Total noncurrent liabilities:6115521
Total liabilities:11338723
Temporary equity, carrying amount    12 
Stockholders' equity
Stockholders' equity attributable to parent, including:188810133
Common stock000002
Additional paid in capital171414402391375363
Accumulated deficit(153)(406)(394)(381)(363)(362)
Warrants and rights outstanding     6
Other undisclosed stockholders' equity attributable to parent     (6)
Other undisclosed stockholders' equity     2
Total stockholders' equity:188810135
TOTAL LIABILITIES AND EQUITY:291211183129

Income statement (P&L) ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Gross profit:  0000
Operating expenses(20)(13)(16)(24)(11)(15)
Other operating income, net
(Other Expenses)
     37
Other undisclosed operating loss     (37)
Operating loss:(20)(13)(16)(23)(10)(14)
Nonoperating income10241028
Debt instrument, convertible, beneficial conversion feature     28
Other nonoperating income102410 
Interest and debt expense(0)  (0)  
Other undisclosed income from continuing operations before equity method investments, income taxes   0  
Income (loss) from continuing operations before equity method investments, income taxes:(20)(12)(14)(19)(1)14
Other undisclosed income from continuing operations before income taxes0     
Income (loss) from continuing operations before income taxes:(19)(12)(14)(19)(1)14
Income tax benefit 0110 
Other undisclosed income from continuing operations0     
Net income (loss):(19)(12)(13)(19)(1)14
Other undisclosed net income attributable to parent     9
Net income (loss) attributable to parent:(19)(12)(13)(19)(1)23
Preferred stock dividends and other adjustments   (2)(10)(1)
Other undisclosed net loss available to common stockholders, basic   (4)  
Net income (loss) available to common stockholders, basic:(19)(12)(13)(24)(11)22
Other undisclosed net loss available to common stockholders, diluted(0)(0)(2)   
Net income (loss) available to common stockholders, diluted:(19)(12)(14)(24)(11)22

Comprehensive Income ($ in millions)

9/30/2019
TTM
12/31/2018
12/31/2017
12/31/2016
12/31/2015
12/31/2014
Net income (loss):(19)(12)(13)(19)(1)14
Comprehensive income (loss), net of tax, attributable to parent:(19)(12)(13)(19)(1)14

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: